Quest Diagnostics (DGX) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup leans toward a beat — consensus is a manageable bar, organic volume momentum from Corewell/Fresenius is still ramping, and advanced diagnostics (Alzheimer's AD-Detect, cardiometabolic) continue to accelerate; the primary wildcard is whether Project Nova expense cadence and elevated fuel costs create a margin drag that offsets top-line strength.

Heading into Q2 2026, the setup for DGX is constructively bullish. Consensus expects revenue of ~$2.97B and adjusted diluted EPS of ~$2.84, both representing meaningful year-over-year growth, yet the bar appears achievable given the structural tailwinds that drove Q1's strong beat. Management guided for "just over 49% of revenue and EPS in the first half," implying Q2 should be roughly in line with Q1's $2.90B revenue run-rate, and the full-year guidance raise post-Q1 (revenue $11.78B–$11.90B; adjusted EPS $10.63–$10.83) already embeds a conservative posture on ACA subsidy headwinds and elevated fuel costs (~$7–10M embedded for the remaining three quarters). Estimate revisions have been remarkably stable since the Q1 print — the Q2 adjusted EPS consensus has barely moved from $2.82 to $2.84 since April 24 — suggesting the Street has not aggressively front-run upside, leaving room for a positive surprise if organic volume ex-Corewell/Fresenius (3.8% in Q1) continues to accelerate. The stock has recovered from its post-earnings dip to trade near $207, roughly flat since the April 21 print, implying the market has not yet priced in a beat. The single biggest wildcard is the Project Nova expense cadence: management flagged that "more than 60% of Nova expenses" will fall in H2, with Q2 representing a ramp from Q1 — any upside surprise on margin could be the catalyst that re-rates the stock, while a larger-than-expected Nova drag could disappoint even on a revenue beat.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar on both revenue (~$2.97B) and adjusted EPS (~$2.84); organic requisition volume growth is the bigger swing factor — consensus sits at ~7.8% for Q2, well below Q1’s 10.8% print, leaving meaningful room for an upside surprise if Corewell/Fresenius ramp continues.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha Consensus and Actuals Data (Total Revenue, Adjusted Diluted EPS, Organic Req. Volume Growth, Revenue per Requisition, Adjusted Operating Income). Q1 2026 actuals and Q2 2025 actuals from Visible Alpha. Q2 2026 consensus as of July 22, 2026. FY 2026 guidance from Quest Diagnostics Q1 2026 Earnings Release (April 21, 2026).

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Pattern: DGX has beaten consensus on both revenue and adjusted EPS in each of the last 8 quarters, with revenue beats averaging ~2.1% and EPS beats averaging ~2.8%, suggesting the Street consistently sets a conservative bar — a pattern that favors a beat heading into Q2 2026. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised both revenue and adjusted EPS guidance at Q1 earnings (April 21) and has not issued any subsequent formal revision; tone remains constructive, with the only incremental headwinds being elevated fuel costs and a heavier Project Nova expense skew to H2.

Sources: Quest Diagnostics Q1 2026 Earnings Release (April 21, 2026); Q1 2026 Earnings Call Transcript (April 21, 2026); Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 print — Q2 revenue consensus has moved only +$0.8M and EPS only +$0.01 since April 24 — suggesting the Street has not aggressively revised up despite the strong Q1 beat, leaving the bar achievable and potential for a positive surprise intact.

Estimates have barely moved since the Q1 print, tracking almost exactly in line with the raised guidance midpoints. The lack of upward revision despite a strong Q1 beat suggests the Street is waiting for confirmation of the Corewell/Fresenius ramp and Project Nova expense cadence before revising higher — a beat on Q2 could catalyze a more meaningful estimate revision cycle. Source: Visible Alpha Consensus and Actuals Data; Quest Diagnostics Q1 2026 Earnings Release.

5. Stock Performance

Key Takeaway: DGX has essentially flat-lined since the Q1 earnings print (+2.3% vs. April 21 close of $205.04), meaningfully underperforming XLV (+9.3%) and the S&P 500 (+6.1%) over the same period, suggesting the market has not priced in a beat and that multiple re-rating — rather than estimate revision — is the primary upside lever.

Since the Q1 2026 earnings date (April 21, 2026), DGX closed at $209.83 on July 23 vs. $205.04 at the prior close, a gain of approximately +2.3%. Over the same period, XLV (Health Care Select Sector SPDR) gained approximately +9.3% (from $145.92 to $159.43) and the S&P 500 (SPY) gained approximately +6.1% (from $704.08 to $747.41). DGX initially sold off sharply in the days following the Q1 print (touching ~$187 in mid-May), before recovering through June and July as the broader healthcare sector rallied. The stock’s underperformance vs. XLV is notable given the strong Q1 beat and guidance raise, and likely reflects investor caution around Project Nova expense ramp, PAMA survey uncertainty, and ACA subsidy headwinds. The 12-month NTM P/E of ~18.4x is modestly above the 12-month-ago level of ~16.5x, with the majority of the 12-month +26% price gain driven by earnings growth rather than multiple expansion. Source: Stock Price Data (Yahoo Finance); Stock Performance Decomposition Data.

Indexed Price Performance: DGX vs. XLV vs. S&P 500 (Since April 21, 2026)

Note: Indexed to 100 at April 21, 2026 close. DGX base = $205.04; XLV base = $145.92; SPY base = $704.08. Source: Stock Price Data (Yahoo Finance).

6. Material News & Developments

Key Takeaway: The most material post-Q1 development is the $500M senior notes offering (May 2026), which signals balance sheet confidence and potential M&A optionality; the Guardant Shield partnership going live in Q1 and the PAMA data collection window opening in May are the key read-throughs for Q2 volume and long-term reimbursement.

• April 21, 2026 — Q1 2026 Earnings Beat & Guidance Raise: DGX reported Q1 revenue of $2.895B (+9.1% YoY) and adjusted EPS of $2.50, both beating consensus by ~2.7% and ~5.0% respectively. Full-year 2026 revenue guidance raised to $11.78B–$11.90B and adjusted EPS to $10.63–$10.83. Organic volume growth of 10.8% was the headline driver, with Corewell Health and Fresenius Medical Care contributing ~7% of that growth. Implication: Sets a high bar for Q2 organic volume expectations; Corewell/Fresenius ramp is the key volume driver to watch.
• May 1–8, 2026 — $500M Senior Notes Offering (8-K): Quest priced and closed a $500M senior notes offering due 2036. Implication: Signals management confidence in cash flow generation and provides dry powder for M&A or capital return; no immediate earnings impact but watch for deployment commentary on Q2 call.
• May 2026 — PAMA Data Collection Survey Opens: The PAMA data collection survey window opened in May and runs through end of July 2026. Management expressed cautious optimism that broader hospital lab participation this cycle could result in upward rate pressure if the RESULTS Act does not pass. Implication: PAMA outcome is a multi-year reimbursement wildcard; broader hospital participation is a potential positive for DGX vs. prior cycles.
• May 21, 2026 — Annual Meeting of Stockholders (8-K): All director nominees elected; executive compensation approved (86.9M for, 7.2M against); PricewaterhouseCoopers ratified as auditor; stockholder proposal for independent board chairman rejected (23.9M for, 69.8M against). Implication: No governance disruption; routine outcome.
• Q1 2026 (Ongoing) — Guardant Shield Partnership Live: The Quest-Guardant collaboration for the Shield colorectal cancer blood test went live in Q1, with Quest performing blood collections and listing the test on its menu. Guardant confirmed at the June 2 William Blair conference that the partnership is "really starting to play into the numbers" and opening doors to health systems where Guardant lacked direct presence. Implication: Incremental volume driver for Quest PSCs; revenue-sharing model means limited direct revenue impact but strategic positioning in CRC screening is significant.
• Q1 2026 (Ongoing) — AD-Detect Alzheimer’s Testing Doubling: Management disclosed that the Alzheimer’s testing book more than doubled year-over-year in Q1 2026, with Quest offering a proprietary algorithm combining multiple biomarkers (amyloid beta, ApoE, p-tau217, p-tau181) with >90% sensitivity/specificity. Implication: Advanced diagnostics mix shift is accelerating; watch for any commentary on Q2 AD-Detect volume trajectory as a leading indicator of advanced diagnostics revenue per requisition.
• Q1 2026 (Ongoing) — Quest AI Companion Launch: Quest launched its AI Companion tool on the myQuest app, with ~350,000 patient engagements since rollout. Implication: Consumer engagement metric; not a near-term revenue driver but supports consumer channel retention and repeat testing rates.
• June 17, 2026 — Q2 2026 Earnings Date Announced: Quest confirmed Q2 2026 results will be released July 23, 2026. No incremental guidance or business update provided.

7. Peer Commentaries — Current-Quarter Read-Through

Key Takeaway: Peer commentary from Labcorp (Q1 earnings April 30 + Jefferies June 3) and Guardant Health (William Blair June 2 + Jefferies June 3) provides the most direct read-through for DGX Q2 2026 — both confirm structural diagnostic demand, accelerating Alzheimer’s/specialty testing, and a healthy hospital outsourcing pipeline, all of which are tailwinds for Quest’s Q2 print.

Methodology note: Only commentary explicitly concerning the peer’s Q2 2026 period, post-Q1 2026 performance trajectory, or active full-year 2026 outlook is included below. Historical Q1 2026 result commentary not framed as a forward-looking signal has been excluded.

Labcorp (LH) — Q1 2026 Earnings Call (April 30, 2026) + Jefferies Global Healthcare Conference (June 3, 2026)

Comparability to DGX: Very High. Labcorp is DGX’s closest direct competitor in clinical laboratory services, with near-identical end markets, channel mix, and reimbursement exposure.

• Structural utilization confirmed for Q2 and beyond: At the June 3 Jefferies conference, Labcorp CFO Julia Wang characterized the utilization environment as "structural" and "durable in nature," driven by aging demographics, diagnostic innovation, and increasing consumer engagement. The test-per-accession trend has been "moving higher consistently and durably post-COVID." DGX Read-Through: Directly validates Quest’s thesis that elevated utilization is not a post-COVID anomaly. Supports the case for Q2 organic volume growth remaining above historical norms.
• Alzheimer’s / Neurology is the fastest-growing specialty: Labcorp disclosed at Jefferies that its neurology franchise grew "strong double digit" in Q1, with Alzheimer’s being the "leading contributor." Esoteric testing now accounts for ~40% of Labcorp’s diagnostic revenue and is growing faster than routine testing. DGX Read-Through: Highly positive. Quest’s AD-Detect book more than doubled YoY in Q1; Labcorp’s confirmation of the same trend across the industry suggests Q2 Alzheimer’s testing momentum is likely sustained.
• Volume/price mix expected ~50/50 for full-year Diagnostics: Labcorp guided to roughly equal contributions from volume and price/mix for its full-year Diagnostic segment revenue growth of 5.1%–5.9%, consistent with 2025. Unit price has been "essentially flattish," with the price benefit coming from mix improvement (shift to higher-value tests). DGX Read-Through: Consistent with Quest’s own revenue-per-requisition dynamics. Supports the consensus estimate of +0.7% revenue per requisition for Q2 2026 as achievable, with mix shift (advanced diagnostics, consumer) as the driver.
• Hospital outsourcing pipeline remains active and accelerating: Labcorp closed "a few transactions" in early 2026 (Empire City Labs, Crouse Health, one unnamed health system) and maintains an "active pipeline of hospitals and regional local labs." CFO Wang noted health systems are "struggling right now and looking for ways to partner." PAMA implementation, if it occurs, is expected to "increase the pipeline of deals." DGX Read-Through: Positive for Quest’s Co-Lab Solutions strategy. Corewell Health and Fresenius are already contributing ~7% to organic volume; the broader outsourcing trend suggests additional partnership opportunities beyond these two.
• ACA exchange headwind quantified at 30 bps for full-year Diagnostics: Labcorp estimated a 30 basis point volume impact from ACA exchange enrollment declines for full-year 2026, noting the Q1 impact was "immaterial." The headwind is embedded in guidance. DGX Read-Through: Quest management similarly retained a modest ACA headwind assumption in full-year guidance despite no measurable Q1 impact. The 30 bps Labcorp estimate provides a useful calibration for the magnitude of risk — manageable but not zero.
• Fuel cost headwind ~$5–10M for full year (Labcorp) vs. $7–10M (Quest): Both companies disclosed similar fuel cost headwinds embedded in guidance, with Labcorp calling it "manageable." DGX Read-Through: Confirms the headwind is industry-wide and already in numbers; no incremental surprise risk from fuel.
• Consumer health growing "very strong double digit" with constructive margins: Labcorp OnDemand (DTC) grew very strong double digit in Q1 and the company remains "optimistic about the growth to come." Margins are "constructive" despite upfront investment. DGX Read-Through: Validates Quest’s consumer channel strategy. Quest’s questhealth.com grew in the high-20s in Q1; Labcorp’s confirmation of similar trends suggests the consumer channel tailwind is industry-wide and likely continued into Q2.
• MolDX approval for advanced tests "taking longer" with more back-and-forth: Labcorp acknowledged at Jefferies that regulatory processes for advanced diagnostic tests (specifically MRD/MolDX) are experiencing delays and increased complexity. DGX Read-Through: Moderate risk. Quest’s Haystack MRD test has PLA codes priced at $3,900 baseline and $800 monitoring; regulatory delays could slow reimbursement ramp for this product.

Guardant Health (GH) — William Blair Growth Stock Conference (June 2, 2026) + Jefferies Global Healthcare Conference (June 3, 2026)

Comparability to DGX: High. Guardant is a direct partner of Quest (Shield CRC test distribution) and a competitor in advanced oncology diagnostics. Commentary on the Quest collaboration is directly relevant.

• Quest collaboration "really starting to play into the numbers" in Q2: Guardant CFO Mike Klein stated at Jefferies (June 3) that the Quest collaboration, which went live toward the end of Q1, is "really starting to play into the numbers" and is providing a "massive step up in connectivity" — opening doors to health systems and physician practices where Guardant lacked direct presence. DGX Read-Through: Directly positive. Quest is generating incremental blood collection volume from Shield orders; the partnership is scaling faster than initially expected, which could be a modest Q2 volume tailwind for Quest PSCs.
• ACS guideline inclusion for Shield — volume driver for remainder of 2026: Shield was included in American Cancer Society guidelines in late May/early June 2026. Klein expects this to have "a positive impact on volume for the remainder of 26," particularly in ~12 states where commercial payers are mandated to cover tests in ACS guidelines. DGX Read-Through: Positive for Quest’s Shield collection volumes in Q2 and H2 2026. Broader Shield adoption means more blood draws at Quest PSCs.
• FDA approval of Guardant360 liquid CDX — not in guidance, provides upside: The FDA approval of Guardant360 liquid CDX was not contemplated in guidance and is expected to "help drive volume" with a "two-fold impact" (liquid + tissue pull-through). Klein noted the attachment rate for tissue with liquid is expected to be "a lot stronger than it was in the past." DGX Read-Through: Moderate positive. Quest performs specimen collection for Guardant tests; higher Guardant360 volumes translate to incremental Quest PSC draw volumes.
• Full-year 2026 revenue guidance raised to ~$1.31B (+33% growth): Guardant raised its full-year guidance at Q1 earnings (May 7) and reiterated at both June conferences, citing strong Q1 traction in oncology and screening, the Quest collaboration, and DTC initiatives. Klein expressed "even more confidence" in the numbers given the ACS guidelines and FDA approval not included in the original guide. DGX Read-Through: Positive industry signal. Guardant’s confidence in accelerating advanced oncology and CRC screening demand is consistent with Quest’s own advanced diagnostics growth narrative.
• Gross margin improvement through ASP optimization and workflow efficiencies: Guardant highlighted "very good progress" on gross margins through ASP optimization, workflow efficiencies, and transition to NovaSeq X. The core business (ex-screening) is "firmly cash flow positive" and expected to remain so for full-year 2026. DGX Read-Through: Moderate positive. Industry-wide margin improvement through technology and workflow optimization is consistent with Quest’s own Invigorate/Project Nova efficiency narrative.

NeoGenomics (NEO) — Jefferies Global Healthcare Conference (June 4, 2026)

Comparability to DGX: Moderate. NEO is a specialized oncology/genomics lab; read-through is most relevant for Quest’s advanced oncology and MRD testing segments.

• Advanced oncology demand "stronger than ever" heading into H2 2026: NEO management expressed strong optimism for H2 2026 following ASCO, noting the company was "oversubscribed" in meetings and that "interest in NeoGenomics is stronger than ever" from both clinical and pharma/CRO perspectives. DGX Read-Through: Weak-to-moderate positive. Broad oncology testing demand is a tailwind for Quest’s oncology segment, though NEO’s specialized focus limits direct comparability.
• MolDX reimbursement for advanced tests "taking longer" — consistent with Labcorp: NEO’s CFO noted that new advanced tests face initial gross margin headwinds due to delayed commercial payer coverage, with the first year or two expected to be a "little bit of a gross margin headwind." NEO has 300+ payer contracts and is actively pursuing coverage for Radar Street. DGX Read-Through: Consistent with Labcorp’s commentary. Reimbursement delays for novel diagnostics are an industry-wide dynamic; Quest’s Haystack MRD faces similar near-term reimbursement ramp risk.
• Technology upgrades (NovaSeq X) driving ~30% cost reduction in sequencing: NEO is transitioning liquid biopsy to NovaSeq X (completing Q3 2026) and heme NGS large panel (completing Q1 2027), expecting ~30% cost leverage. DGX Read-Through: Moderate positive. Technology-driven cost reduction in sequencing is an industry-wide trend that benefits all labs with NGS capabilities, including Quest’s esoteric lab operations.
• Pharma services expected to decline low-single digits in 2026, return to growth in 2027: NEO expects pharma services to be "marginally down, sort of low single digits" in 2026 but sees "increased bookings" as a leading indicator of 2027 recovery. Biotech optimism is described as higher than a year ago. DGX Read-Through: Weak. Quest’s pharma/life sciences data monetization business is a smaller segment; the general biotech optimism is a mild positive for Quest’s life sciences partnerships.

8. Insider Transaction Activity

Key Takeaway: Two insider sales since Q1 earnings, both under pre-established 10b5-1 plans — CEO James Davis sold 10,000 shares on June 1 and SVP Karthik Kuppusamy sold 8,147 shares on June 4; neither is a discretionary signal, and the absence of any open-market purchases is neutral rather than negative given the 10b5-1 context.

Both transactions were executed under pre-established 10b5-1 trading plans and filed within the standard disclosure window. No open-market purchases or discretionary sales were identified in the period since Q1 earnings. The CEO retaining 132,423 shares post-sale is a meaningful ownership stake. Nothing in the insider activity pattern signals concern heading into the print. Source: SEC Form 4 Filings (Insider Transaction Data).

9. Risks & Considerations

Key Takeaway: The risk/reward is asymmetric to the upside given the consistent beat history and stable estimates, but the Project Nova expense ramp and PAMA uncertainty are the two structural risks that could limit multiple expansion even on a beat.

Upside Risks

• Organic volume ex-Corewell/Fresenius accelerates above 3.8% Q1 level: If the physician channel and consumer channel continue to gain share, the underlying organic growth rate (ex-partnerships) could surprise to the upside, driving both revenue and margin beats.
• Advanced diagnostics mix shift accelerates: AD-Detect Alzheimer’s testing more than doubled YoY in Q1; if this trajectory continues or accelerates in Q2, revenue per requisition could inflect positively despite the Corewell/Fresenius mix headwind, driving a margin beat.
• Project Nova expenses come in below the Q2 ramp expectation: Management guided for Nova expenses to "ramp in Q2" before concentrating in H2; if the ramp is slower than feared, adjusted operating margin could beat consensus.
• Consumer channel outperformance: questhealth.com grew in the high-20s in Q1; any acceleration or new partnership announcement (e.g., additional wearable/wellness collaborations) could be a positive catalyst.
• PAMA RESULTS Act progress: Any legislative progress on the RESULTS Act during the PAMA survey window (May–July 2026) could be a significant positive catalyst for long-term reimbursement expectations.

Downside Risks

• Project Nova expense ramp larger than expected: Management flagged >60% of Nova expenses in H2, with Q2 as a ramp quarter. If the ramp is steeper than anticipated, adjusted operating margin could disappoint even on a revenue beat. This is the single biggest near-term margin risk.
• Revenue per requisition disappoints: The Corewell/Fresenius business mix (higher proportion of routine tests) depressed revenue per requisition by 1.3% in Q1. If this mix headwind is larger than expected in Q2, or if advanced diagnostics growth moderates, revenue per requisition could miss consensus of $44.36.
• ACA subsidy expiration impact materializes: Management retained a modest ACA headwind assumption in guidance despite no Q1 impact. If ACA enrollment declines accelerate in Q2 (consistent with Labcorp’s 30 bps estimate), volume could be softer than expected in the physician channel.
• PAMA adverse outcome: If the PAMA data collection survey results in lower-than-expected hospital lab participation, the risk of adverse rate cuts in 2027 increases. While not a Q2 earnings risk, any negative PAMA commentary on the call could weigh on the stock.
• Elevated fuel costs persist or worsen: Quest embedded $7–10M of fuel cost headwind for the remaining three quarters. If fuel prices remain above $4/gallon or increase further, this headwind could be larger than guided.
• Corewell/Fresenius ramp slower than expected: These two partnerships contributed ~7% to Q1 organic volume growth. If the ramp slows or integration challenges emerge, the headline organic volume growth rate could disappoint vs. the consensus expectation of ~7.8%.

Appendix: Key Data Sources & Citations

• Visible Alpha Consensus and Actuals Data — All KPI consensus estimates, actuals, and revision history. Source: Visible Alpha (https://insights.visiblealpha.com/mex/DGX/NMV/IS and /RV).
• Quest Diagnostics Q1 2026 Earnings Release — April 21, 2026. Full-year 2026 guidance, Q1 actuals, operational highlights.
• Quest Diagnostics Q1 2026 Earnings Call Transcript — April 21, 2026. Management commentary on volume, revenue per requisition, advanced diagnostics, consumer channel, Project Nova, fuel costs, Corewell/Fresenius.
• Quest Diagnostics 8-K Filings — May 1, 2026 (Notes Pricing); May 8, 2026 ($500M Senior Notes); May 21, 2026 (Annual Meeting Voting Results).
• Labcorp (LH) Q1 2026 Earnings Call Transcript — April 30, 2026. Q2 2026 outlook, volume/pricing dynamics, PAMA, consumer health, hospital outsourcing.
• Labcorp (LH) Jefferies Global Healthcare Conference Transcript — June 3, 2026. Full-year 2026 guidance reiteration, structural utilization commentary, Alzheimer’s/neurology growth, margin expansion.
• Guardant Health (GH) William Blair Growth Stock Conference Transcript — June 2, 2026. Shield revenue guidance, Quest collaboration update, ACS guideline inclusion.
• Guardant Health (GH) Jefferies Global Healthcare Conference Transcript — June 3, 2026. Q2 2026 volume drivers, FDA approval of Guardant360 liquid CDX, Quest partnership scaling.
• NeoGenomics (NEO) Jefferies Global Healthcare Conference Transcript — June 4, 2026. Advanced oncology demand, MolDX reimbursement delays, technology upgrade timeline.
• SEC Form 4 Filings (Insider Transaction Data) — James E. Davis (June 1, 2026); Karthik Kuppusamy (June 4, 2026). Source: SEC EDGAR (https://www.sec.gov/).
• Stock Price Data — DGX, XLV, SPY daily closing prices April 21 – July 23, 2026. Source: Yahoo Finance.
• Stock Performance Decomposition Data — NTM multiple decomposition (EV/EBITDA, P/E) across 1M, 3M, 6M, 12M horizons. Source: Internal analytics.